Month: July 2024

SHENZHEN, China, July 10, 2024 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (OTCQX: PAIYY) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, is pleased to announce that its American Depositary Shares (the “ADSs”) are now trading on the OTCQX Best Market under the ticker symbol “PAIYY.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com. The OTCQX Best Market is OTC Markets Group’s premier market for established, investor-focused U.S. and international companies. To be eligible, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, and be current in their disclosure. Mr. ZHANG Chen, Chairman of the Company, commented,...

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Aesthetic Medical International Holdings Group Ltd. (OTCQX: PAIYY), a leading provider of aesthetic medical services in China, has qualified to trade on the OTCQX® Best Market. Aesthetic Medical International Holdings Group Ltd. upgraded to OTCQX from the Pink® market. Aesthetic Medical International Holdings Group Ltd. begins trading today on OTCQX under the symbol “PAIYY.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors.  For companies listed on a qualified...

TORONTO, July 10, 2024 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it will host a scheduled conference call to discuss the results for its second quarter ended June 30, 2024 on Thursday, August 8, 2024 at 5:00 p.m. Eastern Time. The Company will report its financial results for the second quarter 2024 the same day after market close.CONFERENCE CALL DETAILS Date: Thursday, August 8, 2024Time: 5:00 p.m. Eastern TimeWebcast: https://app.webinar.net/LVQnp1BkreYDial-in Number: 1-888-664-6392Replay: 416-764-8677 or 1-888-390-0541     Available until 12:00 midnight Eastern Time Thursday, August 22, 2024 Replay Entry Code: 532477#About TerrAscendTerrAscend is a leading...

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. (“Link”), a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody with first-in-class potential that has received Investigational New Drug (“IND”) clearance from the U.S. Food and Drug Administration. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. “We are thrilled to add CT-95, formerly...

CALGARY, Alberta, July 10, 2024 (GLOBE NEWSWIRE) — First Helium Inc. (“First Helium” or the “Company”) (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today announced plans to test key exploration targets at the Company’s 100% owned Worsley property in Northern Alberta, along with key corporate activities, in the second half of 2024. Highlights:The Company plans to test multiple high impact exploration targets over the next 6 months, including:A substantial structure in the Leduc Formation, identified on recently interpreted proprietary 3D seismic (Press Release dated July 3, 2024); and Numerous planned horizontal, helium-enriched natural gas targets on a regional play on the western part of the Worsley property.All targets to be tested in the anticipated program:Have the potential to encounter multiple productive horizons (pay zones)...

Q2-2024 Copper Production of 14.0 million pounds, 2024 Guidance Maintained $3.6M Quarterly Dividend Paid in Q2-2024, Additional $4.8 M Performance Dividend Declared Q2-2024 cash cost1 of $1.96 per pound, Outperforming Guidance Annual Maintenance Shutdown Completed According to Plan VANCOUVER, British Columbia, July 10, 2024 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce production results for the quarter ended June 30, 2024 (“Q2-2024”) from Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile. Dollar amounts in this news release are in U.S. dollars unless indicated otherwise. “During the second quarter, Amerigo’s team at MVC completed its planned annual 8-day maintenance shutdown. Despite the non-planned impact of one...

Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 millionMONTREAL, July 10, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter of fiscal year 2024 ended May 31, 2024 (Q2 2024). All figures are in US dollars unless otherwise stated. Revenue for Q2 2024 and First Half Fiscal 2024 (in thousands of dollars)  Three monthsended May 31 % change Six months ended May 31 % change  2024 2023   2024 2023  EGRIFTA...

– Lomecel-B™ appears to be the first cellular therapeutic candidate to receive RMAT designation for Alzheimer’s DiseaseWa’el HashadWa’el Hashad, CEO, LongeveronNataliya AgafonovaNataliya Agafonova, M.D., Chief Medical Officer, LongeveronJoshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, LongeveronMIAMI, July 10, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease. Lomecel-B™ is a...